Cullgen begins Phase 1 dosing of oral, pan-TRK protein degrader

Cullgen announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader for the treatment of pain. CG001419 is a highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins and is being developed to be a new, non-opioid, non-NSAID analgesic therapy as part of a new class of pain signal inhibitors that have the potential to reduce the risk of addiction associated with other pharmaceutical therapies for the treatment of pain. As previously announced, Cullgen entered into a merger agreement with Pulmatrix (PULM) on November 13, 2024.